SAN FRANCISCO, CA--(Marketwired - September 10, 2015) - CAR T-cell therapies show potential in treating acute myeloid leukemia (AML) and other medical conditions, but there's a lot of work to do before they're ready for commercialization. Alan Leong, senior analyst with BioWatch, updates The Life Sciences Report about the current state of CAR T-cell therapeutics and how some companies are developing bispecific antibodies.
He explains the approach of a number of the companies currently in the sector, including RepliCel Life Sciences Inc. (
The Life Sciences Report: Tell our readers about chimeric antigen receptor (CAR) T-cells and developments in the oncology field, particularly among companies targeting hematologic (blood) cancers.
Alan Leong: We're seeing remarkable and well-documented response rates for CAR T-cell therapies. These therapeutics are still in the early stages of their lifecycles, so they are likely to evolve and be refined over the next five to 10 years. There are a great number of interesting companies. Some of these are very early stage, but they caught my eye because of what they imply…
Continue reading this interview: CAR T-Cell Therapeutics: Alan Leong of BioWatch Looks Beyond the Buzz for Solid Early-Stage Plays
About Streetwise Reports -- The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.
DISCLOSURE:
BioWatch paid The Life Sciences Report to conduct, produce and distribute the interview. Mr. Alan Leong had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Mr. Leong and not of The Life Sciences Report or its officers.
Contact Information:
Brandon Fung